Corcept Stock Crashes 50% After FDA Rejection and Patent Loss Spark Securities Lawsuit

Biotech Giant Faces Securities Lawsuit Following Dramatic Stock Collapse

Corcept Therapeutics ($CORT) faces a significant legal challenge following a catastrophic market decline triggered by an FDA rejection and patent defeat. Litigation firm Hagens Berman has filed a securities class action lawsuit alleging that the company concealed critical FDA warnings regarding insufficient clinical data for its lead drug candidate relacorilant while publicly maintaining confidence in its pipeline readiness. The legal action arrives in the aftermath of a December 31, 2025 Complete Response Letter from the Food and Drug Administration—a decision that sent Corcept's stock into freefall, plummeting 50% from $70.20 to $34.80 and obliterating approximately $2.5 billion in market capitalization in a matter of days.

The timing and magnitude of the decline have prompted investor scrutiny regarding what company leadership knew about regulatory obstacles and when that information became available to the public. The lawsuit alleges a disconnect between Corcept's public messaging about pipeline advancement and the private regulatory communications that reportedly signaled serious obstacles ahead.

The Financial Reckoning and Regulatory Failure

The numbers tell a stark story. Corcept Therapeutics has experienced one of biotech's more dramatic single-event collapses:

• Stock price decline: 50% drop from $70.20 to $34.80 per share
• Market capitalization destruction: $2.5 billion erased from company valuation
• Regulatory catalyst: FDA Complete Response Letter issued December 31, 2025
• Drug candidate affected: Relacorilant, the company's lead pipeline asset
• Legal deadline: Lead Plaintiff motion deadline set for April 21, 2026

The Complete Response Letter represents one of the most serious regulatory outcomes a company can receive. Unlike an approval, the FDA's response indicates that the agency cannot approve the drug in its current form and requires additional clinical data, research, or other evidence before reconsideration. This outcome becomes particularly damaging when investors have been led to believe a drug candidate was further along in development than company communications—both public and private—actually indicated.

The Hagens Berman allegation centers on a critical claim: Corcept knew about FDA concerns regarding insufficient clinical data for relacorilant but continued to publicly tout the readiness of its pipeline without adequate disclosure of these material risks. In regulated industries like pharmaceuticals, this type of alleged concealment falls squarely within the framework of securities fraud, where companies must disclose material risks that could affect investment decisions.

Adding to the company's troubles, Corcept has also suffered a federal court patent loss, though specific details of that intellectual property setback remain important context for long-term shareholder value. Patent defeats in the biotech sector often carry existential implications for companies dependent on proprietary exclusivity for their drug candidates.

Market Context: The Biotech Regulatory Environment

The collapse of Corcept shares reflects broader vulnerabilities in the biotech sector, where regulatory approval represents the critical inflection point between speculative investment and commercialized revenue generation.

Biotech companies inherently carry significant clinical and regulatory risk. The FDA approval pathway requires:

• Preclinical testing in laboratory and animal models
• IND application to initiate human trials
• Phase I, II, and III clinical trials demonstrating safety and efficacy
• New Drug Application (NDA) submission
• FDA review and approval decision (Standard or Priority)

A Complete Response Letter essentially signals that Phase III clinical trial data—or the totality of safety and efficacy evidence—fell short of FDA standards. This represents a significant setback because it suggests either that relacorilant demonstrated insufficient efficacy, safety concerns emerged, or manufacturing and quality issues require resolution.

The steroid receptor modulator class, which encompasses relacorilant, addresses Cushing's syndrome and related endocrine disorders. While Corcept has marketed the drug Korlym (mifepristone) for Cushing's syndrome since 2012, relacorilant represented a next-generation advancement intended to capture expanded market opportunities. The FDA rejection raises questions about whether relacorilant truly represented the clinical improvement that company messaging had suggested.

Competitive pressures in this space add additional context. Other pharmaceutical and biotech companies pursue Cushing's syndrome treatments and endocrine disorder management, making Corcept's pipeline dependence on relacorilant a potential strategic vulnerability when that lead candidate falters.

Investor Implications and Legal Exposure

The securities class action lawsuit creates multiple layers of risk and consequence for Corcept Therapeutics shareholders:

Immediate consequences:

• The $2.5 billion market capitalization loss represents immediate shareholder value destruction
• Class action litigation creates additional legal and financial liability exposure
• Defense costs and potential settlement obligations will further strain finances
• Executive leadership credibility faces scrutiny regarding disclosure practices

Longer-term strategic implications:

• Loss of relacorilant as a pipeline driver eliminates anticipated near-term revenue catalyst
• Patent loss eliminates IP protection for core assets
• Clinical development timeline extends significantly if relacorilant returns to development
• Company must rebuild investor confidence regarding pipeline management and regulatory communication

Why this matters for investors broadly: The Corcept situation exemplifies the hazards of biotech investing when there exists potential misalignment between company messaging and regulatory realities. The allegation of concealment—knowing about FDA data sufficiency concerns while publicly maintaining pipeline readiness—strikes at fundamental investor protection principles. If substantiated, the lawsuit could establish precedent regarding what constitutes adequate disclosure of known regulatory obstacles in biotech companies.

For institutional investors evaluating biotech holdings, the Corcept case serves as a cautionary example. Due diligence must extend beyond public company statements to encompass understanding of regulatory feedback, clinical trial design adequacy, and the specific FDA communication that preceded the Complete Response Letter.

The class action mechanism also creates potential recoverable damages for shareholders who purchased Corcept stock during what the litigation alleges was a period of material nondisclosure. The April 21, 2026 Lead Plaintiff deadline represents the procedural window during which eligible shareholders must move to serve as class representatives.

Looking Forward: Restructuring and Recovery Uncertainty

Corcept Therapeutics now faces a complex recovery path. The company must simultaneously:

1. Address the FDA's specific clinical data concerns regarding relacorilant and determine whether resubmission is viable
2. Manage legal defense and potential settlement of the securities class action
3. Maintain operations and commercialization of existing Korlym revenues
4. Rebuild market credibility regarding regulatory communication transparency
5. Reassess pipeline strategy given the loss of relacorilant as a near-term commercial driver

The outcome remains highly uncertain. Whether Corcept can successfully address FDA objections and ultimately bring relacorilant to market depends on the nature of the clinical data deficiencies. Some Complete Response Letters can be resolved with additional studies; others indicate fundamental efficacy or safety limitations that prove insurmountable.

What remains clear is that Corcept's market valuation has reset dramatically to reflect a biotech company with an approved marketed product (Korlym) but a severely compromised pipeline and mounting legal liability. Shareholders now await both regulatory developments and legal proceedings that will determine whether this represents a temporary correction or a more permanent impairment of company value.